{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:16:18Z","timestamp":1787015778209,"version":"build-2736575974"},"reference-count":54,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":1920,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,11,9]],"date-time":"2020-11-09T00:00:00Z","timestamp":1604880000000},"content-version":"vor","delay-in-days":8,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001250","name":"Morris Animal Foundation","doi-asserted-by":"publisher","award":["D15CA-307"],"award-info":[{"award-number":["D15CA-307"]}],"id":[{"id":"10.13039\/100001250","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001250","name":"Morris Animal Foundation","doi-asserted-by":"publisher","award":["D15CA\u2010307"],"award-info":[{"award-number":["D15CA\u2010307"]}],"id":[{"id":"10.13039\/100001250","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Information regarding efficacy of the angiotensin II receptor blocker, telmisartan, for treatment of proteinuria in dogs is limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the antiproteinuric efficacy of telmisartan, as compared to enalapril, in dogs with chronic kidney disease and persistent, renal proteinuria.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Animals<\/jats:title>\n                    <jats:p>Thirty-nine client-owned dogs with chronic kidney disease and urinary protein-to-creatinine ratio (UPC) &amp;gt; 0.5 (if azotemic) or\u2009\u2265\u20091.0 (if nonazotemic).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this prospective, randomized, double-masked clinical trial, dogs were block randomized, according to presence or absence of azotemia and systemic arterial hypertension, to receive telmisartan (1.0 mg\/kg PO q24h), or enalapril (0.5 mg\/kg PO q12h), and followed for 120\u2009days. Up-titration of study drug dosage on days 30 and 60, and addition of the other study drug at day 90, were performed if UPC\u2009&amp;gt;\u20090.5 was noted at these visits. Percentage change in UPC relative to baseline was calculated for all time points. Data are presented as median (range).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Thirty-nine (20 telmisartan-treated, 19 enalapril-treated) dogs were included. At day 30, percentage change in UPC was greater for telmisartan-treated (\u221265% [\u221295% to 104%]) vs enalapril-treated (\u221235% [\u221274% to 87%]) dogs (P =\u2009.002). Among dogs persistently proteinuric at earlier visits, telmisartan remained superior to enalapril at days 60 (P =\u2009.02) and 90 (P =\u2009.02). No difference in percentage change in UPC between study groups was observed at day 120, when combination therapy was allowed. Combination therapy resulted in relevant azotemia in 4\/13 (31%) dogs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and Clinical Importance<\/jats:title>\n                    <jats:p>Telmisartan might be a suitable first-line therapy for dogs with renal proteinuria.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jvim.15958","type":"journal-article","created":{"date-parts":[[2020,11,9]],"date-time":"2020-11-09T09:42:10Z","timestamp":1604914930000},"page":"2478-2496","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Efficacy of telmisartan for the treatment of persistent renal proteinuria in dogs: A double-masked, randomized clinical trial"],"prefix":"10.1093","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5249-4645","authenticated-orcid":false,"given":"Bianca N.","family":"Louren\u00e7o","sequence":"first","affiliation":[{"name":"College of Veterinary Medicine, University of Georgia Department of Small Animal Medicine & Surgery, , Athens, Georgia,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5476-5963","authenticated-orcid":false,"given":"Amanda E.","family":"Coleman","sequence":"additional","affiliation":[{"name":"College of Veterinary Medicine, University of Georgia Department of Small Animal Medicine & Surgery, , Athens, Georgia,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott A.","family":"Brown","sequence":"additional","affiliation":[{"name":"College of Veterinary Medicine, University of Georgia Department of Small Animal Medicine & Surgery, , Athens, Georgia,","place":["USA"]},{"name":"College of Veterinary Medicine, University of Georgia Department of Physiology & Pharmacology, , Athens, Georgia,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chad W.","family":"Schmiedt","sequence":"additional","affiliation":[{"name":"College of Veterinary Medicine, University of Georgia Department of Small Animal Medicine & Surgery, , Athens, Georgia,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max C.","family":"Parkanzky","sequence":"additional","affiliation":[{"name":"College of Veterinary Medicine, University of Georgia Department of Small Animal Medicine & Surgery, , Athens, Georgia,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4169-374X","authenticated-orcid":false,"given":"Kate E.","family":"Creevy","sequence":"additional","affiliation":[{"name":"College of Veterinary Medicine, University of Georgia Department of Small Animal Medicine & Surgery, , Athens, Georgia,","place":["USA"]},{"name":"College of Veterinary Medicine & Biomedical Sciences, Texas A&M University, College Station Department of Small Animal Clinical Sciences, , Texas,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,11,1]]},"reference":[{"key":"2026020922130456800_jvim15958-bib-0001","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1111\/jvim.12090","article-title":"Chronic kidney disease in dogs in UK veterinary practices: prevalence, risk factors, and survival","volume":"27","author":"O'Neill","year":"2013","journal-title":"J Vet Intern Med"},{"key":"2026020922130456800_jvim15958-bib-0002","first-page":"223","article-title":"BSAVA Manual of Canine and Feline Nephrology and Urology","author":"Brown","year":"2007","edition":"2"},{"key":"2026020922130456800_jvim15958-bib-0003","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/ki.1986.120","article-title":"Canine chronic renal disease: prevalence and types of glomerulonephritis in the dog","volume":"29","author":"Macdougall","year":"1986","journal-title":"Kid Int"},{"key":"2026020922130456800_jvim15958-bib-0004","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/030098587701400101","article-title":"Spontaneous glomerulonephritis in dogs: I. Classification and immunopathology","volume":"14","author":"M\u00fcller-Peddinghaus","year":"1977","journal-title":"Vet Pathol"},{"key":"2026020922130456800_jvim15958-bib-0005","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.cvsm.2012.04.008","article-title":"Chronic kidney disease in dogs and cats","volume":"42","author":"Bartges","year":"2012","journal-title":"Vet Clin Small Anim"},{"key":"2026020922130456800_jvim15958-bib-0006","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1111\/j.1939-1676.2006.tb02892.x","article-title":"Survival of cats with naturally occurring chronic renal failure is related to severity of proteinuria","volume":"20","author":"Syme","year":"2006","journal-title":"J Vet Intern Med"},{"key":"2026020922130456800_jvim15958-bib-0007","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1111\/j.1939-1676.2007.tb03042.x","article-title":"Prognostic factors in cats with chronic kidney disease","volume":"21","author":"King","year":"2007","journal-title":"J Vet Intern Med"},{"key":"2026020922130456800_jvim15958-bib-0008","doi-asserted-by":"crossref","first-page":"393","DOI":"10.2460\/javma.2005.226.393","article-title":"Evaluation of the association between initial proteinuria and morbidity rate or death in dogs with naturally occurring chronic renal failure","volume":"226","author":"Jacob","year":"2005","journal-title":"J Am Vet Med Assoc"},{"key":"2026020922130456800_jvim15958-bib-0009","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1136\/vr.162.5.141","article-title":"Associations between proteinuria, systemic hypertension and glomerular filtration rate in dogs with renal and non-renal diseases","volume":"162","author":"Wehner","year":"2008","journal-title":"Vet Rec"},{"key":"2026020922130456800_jvim15958-bib-0010","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1111\/jvim.15322","article-title":"Factors associated with survival in dogs with chronic kidney disease","volume":"32","author":"Rudinsky","year":"2018","journal-title":"J Vet Intern Med"},{"key":"2026020922130456800_jvim15958-bib-0011","first-page":"67","article-title":"Dietary modification reduces splitting of glomerular basement membranes and delays death due to renal failure in canine X-linked hereditary nephritis","volume":"65","author":"Valli","year":"1991","journal-title":"Lab Invest"},{"key":"2026020922130456800_jvim15958-bib-0012","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0021-9975(97)80016-3","article-title":"Treatment of X-linked hereditary nephritis in Samoyed dogs with angiotensin converting enzyme (ACE) inhibitor","volume":"117","author":"Grodecki","year":"1997","journal-title":"J Comp Pathol"},{"key":"2026020922130456800_jvim15958-bib-0013","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1067\/mlc.2000.105178","article-title":"Effects of dietary polyunsaturated fatty acid supplementation in early renal insufficiency in dogs","volume":"135","author":"Brown","year":"2000","journal-title":"J Lab Clin Med"},{"key":"2026020922130456800_jvim15958-bib-0014","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/j.1939-1676.2005.tb02713.x","article-title":"Assessment and management of proteinuria in dogs and cats: 2004 ACVIM Forum Consensus Statement (small animal)","volume":"19","author":"Lees","year":"2005","journal-title":"J Vet Intern Med"},{"key":"2026020922130456800_jvim15958-bib-0015","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1111\/jvim.12230","article-title":"Consensus recommendations for standard therapy of glomerular disease in dogs","volume":"27","author":"Brown","year":"2013","journal-title":"J Vet Intern Med"},{"key":"2026020922130456800_jvim15958-bib-0016","doi-asserted-by":"crossref","first-page":"321","DOI":"10.2460\/ajvr.2003.64.321","article-title":"Evaluation of the effects of inhibition of angiotensin converting enzyme with enalapril in dogs with induced chronic renal insufficiency","volume":"64","author":"Brown","year":"2003","journal-title":"Am J Vet Res"},{"key":"2026020922130456800_jvim15958-bib-0017","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1111\/j.1939-1676.2000.tb02271.x","article-title":"Effects of enalapril versus placebo as a treatment for canine idiopathic glomerulonephritis","volume":"14","author":"Grauer","year":"2000","journal-title":"J Vet Intern Med"},{"key":"2026020922130456800_jvim15958-bib-0018","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.semnephrol.2003.11.003","article-title":"Angiotensin receptor blockers in diabetic nephropathy: renal and cardiovascular end points","volume":"24","author":"Parving","year":"2004","journal-title":"Sem Nephrol"},{"key":"2026020922130456800_jvim15958-bib-0019","doi-asserted-by":"crossref","first-page":"90","DOI":"10.7326\/0003-4819-139-2-200307150-00008","article-title":"Effect of losartan on microalbuminuria in normotensive patients with type 2 diabetes mellitus. A randomized clinical trial","volume":"139","author":"Zandbergen","year":"2003","journal-title":"Ann Intern Med"},{"key":"2026020922130456800_jvim15958-bib-0020","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1056\/NEJMoa011489","article-title":"The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes","volume":"345","author":"Parving","year":"2001","journal-title":"N Engl J Med"},{"key":"2026020922130456800_jvim15958-bib-0021","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1161\/01.CIR.0000024416.33113.0A","article-title":"Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect","volume":"106","author":"Viberti","year":"2002","journal-title":"Circulation"},{"key":"2026020922130456800_jvim15958-bib-0022","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.amjmed.2003.09.034","article-title":"The renin-angiotensin-aldosterone system and the kidney: effects on kidney disease","volume":"116","author":"Brewster","year":"2004","journal-title":"Am J Med"},{"key":"2026020922130456800_jvim15958-bib-0023","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.amjhyper.2004.11.032","article-title":"Mechanisms for the clinical benefits of angiotensin II receptor blockers","volume":"18","author":"Schmieder","year":"2005","journal-title":"Am J Hypert"},{"key":"2026020922130456800_jvim15958-bib-0024","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/nrd873","article-title":"Drugs targeting the renin-angiotensin-aldosterone system","volume":"1","author":"Zaman","year":"2002","journal-title":"Nat Rev Drug Disc"},{"key":"2026020922130456800_jvim15958-bib-0025","article-title":"USP General Chapter 795 Pharmaceutical Compounding\u2014Nonsterile preparations","author":"USP","year":"2019"},{"key":"2026020922130456800_jvim15958-bib-0026","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1093\/ajhp\/55.11.1155","article-title":"Stability of enalapril maleate in three extemporaneously prepared oral liquids","volume":"55","author":"Nahata","year":"1998","journal-title":"Am J Health Syst Pharm"},{"key":"2026020922130456800_jvim15958-bib-0027","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3109\/10837450.2013.860552","article-title":"Physicochemical stability of captopril and enalapril extemporaneous formulations for pediatric patients","volume":"20","author":"Casas","year":"2015","journal-title":"Pharm Dev Technol"},{"key":"2026020922130456800_jvim15958-bib-0028","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1093\/ajhp\/55.18.1915","article-title":"Stability of alprazolam, chloroquine phosphate, cisapride, enalapril maleate, and hydralazine hydrochloride in extemporaneously compounded oral liquids","volume":"55","author":"Allen","year":"1998","journal-title":"Am J Health Syst Pharm"},{"key":"2026020922130456800_jvim15958-bib-0029","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/jppr1997275395","article-title":"Stability of enalapril solutions prepared from tablets in sterile water","volume":"27","author":"Schlatter","year":"1997","journal-title":"Aust J Hosp Pharm"},{"key":"2026020922130456800_jvim15958-bib-0030","first-page":"151","article-title":"The stability of an enalapril maleate oral solution prepared from tablets","volume":"24","author":"Boulton","year":"1994","journal-title":"Aust J Hosp Pharm"},{"key":"2026020922130456800_jvim15958-bib-0031","first-page":"e6","article-title":"Stability of extemporaneous enalapril maleate suspensions for pediatric use prepared from commercially available tablets","volume":"66","author":"Sosnowska","year":"2009","journal-title":"Acta Pol Pharm"},{"key":"2026020922130456800_jvim15958-bib-0032","first-page":"216","article-title":"Enalapril Maleate","author":"Trissel","year":"2018","edition":"6"},{"key":"2026020922130456800_jvim15958-bib-0033","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/bdd.241","article-title":"Pharmacokinetic assessment of an oral enalapril suspension for use in children","volume":"21","author":"Rippley","year":"2000","journal-title":"Biopharm Drug Dispos"},{"key":"2026020922130456800_jvim15958-bib-0034","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1177\/00912700122012661","article-title":"The pharmacokinetics of enalapril in children and infants with hypertension","volume":"41","author":"Wells","year":"2001","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"2026020922130456800_jvim15958-bib-0035","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1111\/jvim.15331","article-title":"ACVIM consensus statement: guidelines for the identification, evaluation, and management of systemic hypertension in dogs and cats","volume":"32","author":"Acierno","year":"2018","journal-title":"J Vet Intern Med"},{"key":"2026020922130456800_jvim15958-bib-0036","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/j.1939-165X.2009.00167.x","article-title":"The use of pooled vs serial urine samples to measure urine protein:creatinine ratios","volume":"39","author":"LeVine","year":"2010","journal-title":"Vet Clin Pathol"},{"key":"2026020922130456800_jvim15958-bib-0037","first-page":"1","article-title":"Recent Advances in Clinical Trial Design and Analysis, Cancer Treatment and Research","author":"DeMets","year":"1995"},{"key":"2026020922130456800_jvim15958-bib-0038","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/j.ijcard.2012.04.058","article-title":"Effects of telmisartan on proteinuria or albuminuria: a meta-analysis of randomized trials","volume":"167","author":"Takagi","year":"2013","journal-title":"Int J Cardiol"},{"key":"2026020922130456800_jvim15958-bib-0039","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1111\/jvim.12471","article-title":"Telmisartan treatment of refractory proteinuria in a dog","volume":"28","author":"Bugbee","year":"2014","journal-title":"J Vet Intern Med"},{"key":"2026020922130456800_jvim15958-bib-0040","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1253\/circj.68.361","article-title":"Rationale for the use of combination angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker therapy in heart failure","volume":"68","author":"Yasumura","year":"2004","journal-title":"Circ J"},{"key":"2026020922130456800_jvim15958-bib-0041","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1161\/01.CIR.99.20.2658","article-title":"Augmented short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure. Vasodilator Heart Failure Trial (V-HeFT) Study Group","volume":"99","author":"Baruch","year":"1999","journal-title":"Circulation"},{"key":"2026020922130456800_jvim15958-bib-0042","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1093\/ndt\/gfi310","article-title":"Effect of low-dose dual blockade of renin-angiotensin system on urinary TGF-beta in type 2 diabetic patients with advanced kidney disease","volume":"21","author":"Song","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"2026020922130456800_jvim15958-bib-0043","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1111\/j.1523-1755.2005.00145.x","article-title":"Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications","volume":"67","author":"Wolf","year":"2005","journal-title":"Kid Int"},{"key":"2026020922130456800_jvim15958-bib-0044","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.semnephrol.2004.01.003","article-title":"Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for IgA nephropathy","volume":"24","author":"Dillon","year":"2004","journal-title":"Sem Nephrol"},{"key":"2026020922130456800_jvim15958-bib-0045","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.pop.2014.08.002","article-title":"Renin-angiotensin-aldosterone system inhibition","volume":"41","author":"Mercier","year":"2014","journal-title":"Prim Care"},{"key":"2026020922130456800_jvim15958-bib-0046","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1001\/archinte.167.18.1930","article-title":"Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials","volume":"167","author":"Phillips","year":"2007","journal-title":"Arch Intern Med"},{"key":"2026020922130456800_jvim15958-bib-0047","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1111\/ijcp.12803","article-title":"Calibrating the impact of dual RAAS blockade on the heart and the kidney\u2014balancing risks and benefits","volume":"70","author":"Ziff","year":"2016","journal-title":"Int J Clin Pract"},{"key":"2026020922130456800_jvim15958-bib-0048","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1093\/oxfordjournals.ndt.a092076","article-title":"Acute renal failure after the use of angiotensin-converting-enzyme inhibitors in patients without renal artery stenosis","volume":"7","author":"Bridoux","year":"1992","journal-title":"Nephrol Dial Transplant"},{"key":"2026020922130456800_jvim15958-bib-0049","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.2215\/CJN.08611209","article-title":"Renin-angiotensin-aldosterone system blockade effects on the kidney in the elderly: benefits and limitations","volume":"5","author":"Turgut","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026020922130456800_jvim15958-bib-0050","doi-asserted-by":"crossref","DOI":"10.1136\/vetreccr-2017-000471","article-title":"Effect of a combination of telmisartan and amlodipine in hypertensive dogs","volume":"6","author":"Caro-Vadillo","year":"2018","journal-title":"Vet Rec Case Rep"},{"key":"2026020922130456800_jvim15958-bib-0051","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1124\/mol.113.091157","article-title":"Mechanism of erythropoietin regulation by angiotensin II","volume":"85","author":"Kim","year":"2014","journal-title":"Mol Pharmacol"},{"key":"2026020922130456800_jvim15958-bib-0052","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1007\/s004249900238","article-title":"Dose-dependent effect of angiotensin II on human erythropoietin production","volume":"439","author":"Freudenthaler","year":"2000","journal-title":"Pfl\u00fcgers Arch"},{"key":"2026020922130456800_jvim15958-bib-0053","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1172\/JCI119769","article-title":"Angiotensin II stimulates proliferation of normal early erythroid progenitors","volume":"100","author":"Mrug","year":"1997","journal-title":"J Clin Invest"},{"key":"2026020922130456800_jvim15958-bib-0054","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.1111\/jvim.12247","article-title":"Prevalence of immune-complex glomerulonephritides in dogs biopsied for suspected glomerular disease: 501 cases (2007-2012)","volume":"27","author":"Schneider","year":"2013","journal-title":"J Vet Intern Med"}],"updated-by":[{"DOI":"10.1111\/jvim.16133","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2021,5,5]],"date-time":"2021-05-05T00:00:00Z","timestamp":1620172800000}}],"container-title":["Journal of Veterinary Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvim.15958","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jvim.15958","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/34\/6\/2478\/66661652\/jvim15958.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/34\/6\/2478\/66661652\/jvim15958.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T03:25:58Z","timestamp":1770693958000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jvim\/article\/34\/6\/2478\/8448446"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,1]]},"references-count":54,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,11,1]]}},"URL":"https:\/\/doi.org\/10.1111\/jvim.15958","relation":{},"ISSN":["1939-1676"],"issn-type":[{"value":"1939-1676","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,11]]},"published":{"date-parts":[[2020,11,1]]},"assertion":[{"value":"2020-03-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-23","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-09","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}